The Experts below are selected from a list of 27 Experts worldwide ranked by ideXlab platform
John S. Kovach - One of the best experts on this subject based on the ideXlab platform.
-
Phase I–II study of Pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma
Investigational New Drugs, 1991Co-Authors: S. R. Patel, Larry K. Kvols, Joseph Rubin, Michael J. O'connell, John H. Edmonson, M. M. Ames, John S. KovachAbstract:Pibenzimol is a fluorescent molecule known to bind to double stranded DNA. It also induces prolongation of the G_2 phase of the cell cycle, inhibition of DNA replication and cessation of the growth of some cells in late S phase after DNA content has been doubled. It has been shown to increase the life span of mice bearing intraperitoneally implanted L1210 and P388 leukemia. These factors coupled with the affinity of Pibenzimol for pancreatic tissue led us to conduct a phase I–II trial of Pibenzimol hydrochloride in patients with advanced pancreatic cancer. Twenty-six patients were treated with a five day continuous infusion of Pibenzimol at a dose ranging from 6–28 mg/m^2/d. There were no treatment related deaths. Major toxicity was hyperglycemia which was self-limited. No objective responses were noted.
-
Phase I-II study of Pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma.
Investigational New Drugs, 1991Co-Authors: Shreyaskumar Patel, Matthew M. Ames, Larry K. Kvols, Joseph Rubin, Michael J. O'connell, John H. Edmonson, John S. KovachAbstract:Pibenzimol is a fluorescent molecule known to bind to double stranded DNA. It also induces prolongation of the G2 phase of the cell cycle, inhibition of DNA replication and cessation of the growth of some cells in late S phase after DNA content has been doubled. It has been shown to increase the life span of mice bearing intraperitoneally implanted L1210 and P388 leukemia. These factors coupled with the affinity of Pibenzimol for pancreatic tissue led us to conduct a phase I–II trial of Pibenzimol hydrochloride in patients with advanced pancreatic cancer. Twenty-six patients were treated with a five day continuous infusion of Pibenzimol at a dose ranging from 6–28 mg/m2/d. There were no treatment related deaths. Major toxicity was hyperglycemia which was self-limited. No objective responses were noted.
S. R. Patel - One of the best experts on this subject based on the ideXlab platform.
-
Phase I–II study of Pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma
Investigational New Drugs, 1991Co-Authors: S. R. Patel, Larry K. Kvols, Joseph Rubin, Michael J. O'connell, John H. Edmonson, M. M. Ames, John S. KovachAbstract:Pibenzimol is a fluorescent molecule known to bind to double stranded DNA. It also induces prolongation of the G_2 phase of the cell cycle, inhibition of DNA replication and cessation of the growth of some cells in late S phase after DNA content has been doubled. It has been shown to increase the life span of mice bearing intraperitoneally implanted L1210 and P388 leukemia. These factors coupled with the affinity of Pibenzimol for pancreatic tissue led us to conduct a phase I–II trial of Pibenzimol hydrochloride in patients with advanced pancreatic cancer. Twenty-six patients were treated with a five day continuous infusion of Pibenzimol at a dose ranging from 6–28 mg/m^2/d. There were no treatment related deaths. Major toxicity was hyperglycemia which was self-limited. No objective responses were noted.
John Macdonald - One of the best experts on this subject based on the ideXlab platform.
-
Phase II study of Pibenzimol in pancreatic cancer
Investigational New Drugs, 1991Co-Authors: Eric H. Kraut, Tom Fleming, Mark Segal, James A. Neidhart, Brent C. Behrens, John MacdonaldAbstract:Twenty-three patients with advanced pancreatic adenocarcinoma were treated with Pibenzimol utilizing a daily intravenous schedule for five days. There were no objective responses seen. The major toxicity was pancreatic with grade 3 hyperglycemia in eleven patients. Pibenzimol is inactive in patients with advanced pancreatic adenocarcinoma.
Larry K. Kvols - One of the best experts on this subject based on the ideXlab platform.
-
Phase I–II study of Pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma
Investigational New Drugs, 1991Co-Authors: S. R. Patel, Larry K. Kvols, Joseph Rubin, Michael J. O'connell, John H. Edmonson, M. M. Ames, John S. KovachAbstract:Pibenzimol is a fluorescent molecule known to bind to double stranded DNA. It also induces prolongation of the G_2 phase of the cell cycle, inhibition of DNA replication and cessation of the growth of some cells in late S phase after DNA content has been doubled. It has been shown to increase the life span of mice bearing intraperitoneally implanted L1210 and P388 leukemia. These factors coupled with the affinity of Pibenzimol for pancreatic tissue led us to conduct a phase I–II trial of Pibenzimol hydrochloride in patients with advanced pancreatic cancer. Twenty-six patients were treated with a five day continuous infusion of Pibenzimol at a dose ranging from 6–28 mg/m^2/d. There were no treatment related deaths. Major toxicity was hyperglycemia which was self-limited. No objective responses were noted.
-
Phase I-II study of Pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma.
Investigational New Drugs, 1991Co-Authors: Shreyaskumar Patel, Matthew M. Ames, Larry K. Kvols, Joseph Rubin, Michael J. O'connell, John H. Edmonson, John S. KovachAbstract:Pibenzimol is a fluorescent molecule known to bind to double stranded DNA. It also induces prolongation of the G2 phase of the cell cycle, inhibition of DNA replication and cessation of the growth of some cells in late S phase after DNA content has been doubled. It has been shown to increase the life span of mice bearing intraperitoneally implanted L1210 and P388 leukemia. These factors coupled with the affinity of Pibenzimol for pancreatic tissue led us to conduct a phase I–II trial of Pibenzimol hydrochloride in patients with advanced pancreatic cancer. Twenty-six patients were treated with a five day continuous infusion of Pibenzimol at a dose ranging from 6–28 mg/m2/d. There were no treatment related deaths. Major toxicity was hyperglycemia which was self-limited. No objective responses were noted.
Joseph Rubin - One of the best experts on this subject based on the ideXlab platform.
-
Phase I–II study of Pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma
Investigational New Drugs, 1991Co-Authors: S. R. Patel, Larry K. Kvols, Joseph Rubin, Michael J. O'connell, John H. Edmonson, M. M. Ames, John S. KovachAbstract:Pibenzimol is a fluorescent molecule known to bind to double stranded DNA. It also induces prolongation of the G_2 phase of the cell cycle, inhibition of DNA replication and cessation of the growth of some cells in late S phase after DNA content has been doubled. It has been shown to increase the life span of mice bearing intraperitoneally implanted L1210 and P388 leukemia. These factors coupled with the affinity of Pibenzimol for pancreatic tissue led us to conduct a phase I–II trial of Pibenzimol hydrochloride in patients with advanced pancreatic cancer. Twenty-six patients were treated with a five day continuous infusion of Pibenzimol at a dose ranging from 6–28 mg/m^2/d. There were no treatment related deaths. Major toxicity was hyperglycemia which was self-limited. No objective responses were noted.
-
Phase I-II study of Pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma.
Investigational New Drugs, 1991Co-Authors: Shreyaskumar Patel, Matthew M. Ames, Larry K. Kvols, Joseph Rubin, Michael J. O'connell, John H. Edmonson, John S. KovachAbstract:Pibenzimol is a fluorescent molecule known to bind to double stranded DNA. It also induces prolongation of the G2 phase of the cell cycle, inhibition of DNA replication and cessation of the growth of some cells in late S phase after DNA content has been doubled. It has been shown to increase the life span of mice bearing intraperitoneally implanted L1210 and P388 leukemia. These factors coupled with the affinity of Pibenzimol for pancreatic tissue led us to conduct a phase I–II trial of Pibenzimol hydrochloride in patients with advanced pancreatic cancer. Twenty-six patients were treated with a five day continuous infusion of Pibenzimol at a dose ranging from 6–28 mg/m2/d. There were no treatment related deaths. Major toxicity was hyperglycemia which was self-limited. No objective responses were noted.